The startup company Novel Concepts Medical is delighted to announce another major breakthrough in its research of COVID-19.

Its novel plant-based treatment has resulted in successfully inhibiting the COVID-19 Omicron variant and blocking its connection to human cells.

Earlier testing demonstrated:

• Stopping the COVID-19 virus’s entry to the cells and stopping its progress
• In case studies, volunteers had negative PCR results within 48 hours and quickly recovered from more than 16 symptoms of long COVID-19, including memory loss, loss of taste and smell, headaches, fatigue, and many symptoms that are common to both COVID-19 and the flu.

"Our cure can STOP Omicron, the COVID-19 virus, and Long COVID-19 symptoms. We can help reduce the high numbers of people catching COVID-19 every week. We can also help provide emergency assistance to those countries that have low vaccination rates. Our plant-based cure is safe and without any known side effects," said founder and inventor, Dr. Rachel Alkalay.

Our company is welcoming emergency testing requests from all countries around the world, rich or poor. The novel medicine can be stored at room temperature and is made from safe and already approved compounds. We are delighted it is also eco-friendly and that it also treats flu symptoms.

Dr. Alkalay added that due to the fact that all its compounds are approved for other uses, she believes the road to get emergency use authorization will be faster. The company, which has a vast array of life-saving medicines, including a dementia and memory-loss cure that was successfully tested on many Long COVID-19 volunteers, is planning to hold an initial public offering in 2022.

Our company has worked with two labs on its research. The first is the Centre for Microbial Chemical Biology at the Michael G. DeGroot Institute for Infectious Disease Research at McMaster University in Ontario, Canada. This lab is led by Dr. Tracey Campbell, who has a PhD in Biochemistry and Biomedical Sciences and a Postdoctoral Fellow from Princeton University. The second is the Smart Assays Lab in the Weizmann Science Park in Israel. This lab is led by Dr. Raphael Mayer, who has a PhD in Biological Chemistry from The Hebrew University of Jerusalem and was a Postdoctoral Fellow at The Rockefeller University.